Information  X 
Enter a valid email address

Lipoxen PLC (XEN)

  Print      Mail a friend

Wednesday 30 June, 2010

Lipoxen PLC

Result of Annual General Meet

RNS Number : 5581O
Lipoxen PLC
30 June 2010
 



FOR IMMEDIATE RELEASE

30 June 2010

 

 

 

Lipoxen plc

 

('Lipoxen' or 'the Company')

 

Result of Annual General Meeting

 

Lipoxen plc (AIM: LPX), a bio-pharmaceutical company specialising in the development of high-value differentiated biologicals, vaccines and siRNA delivery, announces that at its 2010 Annual General Meeting which was held at 2.00pm today, all resolutions put to shareholders were duly passed.

 

- Ends -

 

For further information, please contact:

Enquiries 

Lipoxen plc

+44 (0)20 7389 5015

M. Scott Maguire, Chief Executive Officer




Singer Capital Markets (nominated adviser)

+44 (0)20 3205 7500

Jeff Keating / Claes Spång




Buchanan Communications

+44 (0)20 7466 5000

Lisa Baderoon, Catherine Breen


 

About Lipoxen

Lipoxen plc is a biopharmaceutical company focused on the development of new and improved biologic drugs and vaccines.  Lipoxen has three proprietary patented technology platforms:

 

1) PolyXen - for extending the efficacy and half life of biologic drugs

2) ImuXen - for creating new vaccines and improving existing vaccines

3) SiRNAblate - for the delivery of siRNA

 

Lipoxen's technology is designed to improve the efficacy, safety, stability, biological half-life and immunologic characteristics of its products. 

 

Lipoxen has multiple drug and vaccine programmes in development.  Two products are in clinical development, SuliXen, a long acting insulin and ErepoXen, a long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes vaccines against HIV, influenza and malaria and an exclusive license deal with Baxter Healthcare for blood coagulation drugs.

 

The Company has a low-risk business model and out-licenses its proprietary technologies to biopharmaceutical companies that have strong manufacturing and marketing capabilities.  Lipoxen currently has commercial agreements with some of the world's leading biotechnology and pharmaceutical companies including Baxter, Schering-Plough, the Serum Institute of India Limited, Genentech, and Genzyme. Furthermore, Baxter, the Company's third largest shareholder, and management led the £2.9 million fundraising that the Company announced in May 2009. This fundraising was followed up by a £1.2 million placing in April 2010 which was led by the Company's management team.

 

Lipoxen, which was founded in 1997, trades on the AIM Market of the London Stock Exchange under the ticker symbol LPX. More information can be found at the Company's website: www.lipoxen.com.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RAGSDFFLSFSSEFM